Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease

详细信息    查看全文

• 作者：Paibel Aguayo-Hiraldo^a ; ^b ; Reuben Arasaratnam^b ; Rayne H. Rouce^a ; ^b ; ^{rhrouce@txch.org" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Epstein-Barr virus ; Post-transplant lymphoproliferative disease ; Immunotherapy ; Hematopoietic stem cell transplant ; Solid organ transplant
• 刊名：Boletín Médico del Hospital Infantil de México
• 出版年：2016
• 出版时间：January-February 2016
• 年：2016
• 卷：73
• 期：1
• 页码：31-40
• 全文大小：1142 K

文摘

Fifty years after the first reports of Epstein-Barr virus (EBV)-associated endemic Burkitt's lymphoma, EBV has emerged as the third most prevalent oncogenic virus worldwide. EBV infection is associated with various malignancies including Hodgkin and non-Hodgkin lymphoma, NK/T-cell lymphoma and nasopharyngeal carcinoma. Despite the highly specific immunologic control in the immunocompetent host, EBV can cause severe complications in the immunocompromised host (namely, post-transplant lymphoproliferative disease). This is particularly a problem in patients with delayed immune reconstitution post-hematopoietic stem cell transplant or solid organ transplant. Despite advances in diagnostic techniques and treatment algorithms allowing earlier identification and treatment of patients at highest risk, mortality rates remain as high as 90% if not treated early. The cornerstones of treatment include reduction in immunosuppression and in vivo B cell depletion with an anti-CD20 monoclonal antibody. However, these treatment modalities are not always feasible due to graft rejection, emergence of graft vs. host disease, and toxicity. Newer treatment modalities include the use of adoptive T cell therapy, which has shown promising results in various EBV-related malignancies. In this article we will review recent advances in risk factors, diagnosis and management of EBV-associated malignancies, particularly post-transplant lymphoproliferative disease. We will also discuss new and innovative treatment options including adoptive T cell therapy as well as management of special situations such as chronic active EBV and EBV-associated hemophagocytic lymphohistiocytosis.